Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia

Francesco Paolo Tambaro; Harjeet Singh; Emily Jones; Michael Rytting; Kris M. Mahadeo; Philip Thompson; Naval Daver; Courtney DiNardo; Tapan Kadia; Guillermo Garcia-Manero; Tim Chan; Rutul R. Shah; William G. Wierda

doi:10.1038/s41375-021-01232-2

Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia

Francesco Paolo Tambaro, Harjeet Singh, Emily Jones, Michael Rytting, Kris M. Mahadeo, Philip Thompson, Naval Daver, Courtney DiNardo, Tapan Kadia, Guillermo Garcia-Manero, Tim Chan, Rutul R. Shah, William G. Wierda

Research output: Contribution to journal › Article › peer-review

63 Scopus citations

Original language	English (US)
Pages (from-to)	3282-3286
Number of pages	5
Journal	Leukemia
Volume	35
Issue number	11
DOIs	https://doi.org/10.1038/s41375-021-01232-2
State	Published - Nov 2021

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/s41375-021-01232-2

Cite this

@article{bfb3e63d6af2487aabebc3d96a1f7dab,

title = "Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia",

author = "Tambaro, {Francesco Paolo} and Harjeet Singh and Emily Jones and Michael Rytting and Mahadeo, {Kris M.} and Philip Thompson and Naval Daver and Courtney DiNardo and Tapan Kadia and Guillermo Garcia-Manero and Tim Chan and Shah, {Rutul R.} and Wierda, {William G.}",

note = "Funding Information: Funding This study and correlative laboratory investigations were funded by Ziopharm. Funding Information: Conflict of interest FPT: No relevant conflicts of interest to report. HS: Research funding from Precigen/Intrexon. EJ: No relevant conflicts of interest to report. MR: No relevant conflicts of interest to report. KM: No relevant conflicts of interest to report. PT: No relevant conflicts of interest to report. ND: No relevant conflicts of interest to report. CD: No relevant conflicts of interest to report. TK: No relevant conflicts of interest to report. GGM: No relevant conflicts of interest to report. TC: Employee of Precigen/Intrexon. RRS: Employee of Precigen/Intrexon. WGW: No relevant conflicts of interest to report.",

year = "2021",

month = nov,

doi = "10.1038/s41375-021-01232-2",

language = "English (US)",

volume = "35",

pages = "3282--3286",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "11",

}

TY - JOUR

T1 - Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia

AU - Tambaro, Francesco Paolo

AU - Singh, Harjeet

AU - Jones, Emily

AU - Rytting, Michael

AU - Mahadeo, Kris M.

AU - Thompson, Philip

AU - Daver, Naval

AU - DiNardo, Courtney

AU - Kadia, Tapan

AU - Garcia-Manero, Guillermo

AU - Chan, Tim

AU - Shah, Rutul R.

AU - Wierda, William G.

N1 - Funding Information: Funding This study and correlative laboratory investigations were funded by Ziopharm. Funding Information: Conflict of interest FPT: No relevant conflicts of interest to report. HS: Research funding from Precigen/Intrexon. EJ: No relevant conflicts of interest to report. MR: No relevant conflicts of interest to report. KM: No relevant conflicts of interest to report. PT: No relevant conflicts of interest to report. ND: No relevant conflicts of interest to report. CD: No relevant conflicts of interest to report. TK: No relevant conflicts of interest to report. GGM: No relevant conflicts of interest to report. TC: Employee of Precigen/Intrexon. RRS: Employee of Precigen/Intrexon. WGW: No relevant conflicts of interest to report.

PY - 2021/11

Y1 - 2021/11

UR - http://www.scopus.com/inward/record.url?scp=85104089761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85104089761&partnerID=8YFLogxK

U2 - 10.1038/s41375-021-01232-2

DO - 10.1038/s41375-021-01232-2

M3 - Article

C2 - 33833386

AN - SCOPUS:85104089761

SN - 0887-6924

VL - 35

SP - 3282

EP - 3286

JO - Leukemia

JF - Leukemia

IS - 11

ER -

Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this